Recce Pharmaceuticals (ASX:RCE) secured approval from the Human Research Ethics Committee to investigate the use of the Recce 327 topical gel in a phase 3 trial in patients with diabetic foot ulcers, according to a Monday filing with the Australian bourse.
The receipt of the approval means the company met the safety and efficacy testing required to proceed with the large-scale trial.
The 12-month trial will be conducted in Indonesia, with regulatory submission anticipated for late 2025, the filing said.
The company's shares closed up more than 3% Monday.
Price (AUD): $0.49, Change: $+0.02, Percent Change: +3.19%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.